Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A

Clinical Summary

Celiac Disease: Screening

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Population Asymptomatic adults, adolescents, and children
Recommendation No recommendation.
Grade: I (insufficient evidence)
Risk Assessment Persons at increased risk for celiac disease include those who have a positive family history (eg, a first- or second-degree relative) and persons with other autoimmune diseases (eg, type 1 diabetes mellitus, inflammatory luminal gastrointestinal disorders, Down syndrome, Turner syndrome, IgA deficiency, and IgA nephropathy).
Screening Tests Screening for celiac disease is typically not performed in average-risk persons. The standard method of diagnosing celiac disease is the tissue transglutaminase IgA test, followed by intestinal biopsy for histologic confirmation.
Treatment Treatment of celiac disease is lifelong adherence to a gluten-free diet, which reverses disease manifestations in a majority of patients.
Balance of Benefits and Harms The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for celiac disease in asymptomatic persons.

For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to www.uspreventiveservicestaskforce.org.

Current as of: March 2017

Internet Citation: Clinical Summary: Celiac Disease: Screening. U.S. Preventive Services Task Force. March 2017.
https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/celiac-disease-screening

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857